Overview

Pain Management Drugs Market is forecasted to value over USD 91.6 billion by 2027 end and register a CAGR of 3.5% from the forecast period 2020-2027.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Pain Management Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of the market.
According to the research study conducted by FutureWise research analysts, the Pain Management Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the Pain Management Drugs Market along with the growth opportunities present across this business vertical.

Major players included in the Pain Management Drugs Market are:    
• Novartis AG
• Eli Lilly & Company
• Abbott Laboratories
• Endo Health Solutions, Inc.
• Purdue Pharma L.P.
• Pfizer, Inc.
• F. Hoffmann La Roche Ltd.
• Merck & Co. Inc.
• Johnson & Johnson
• GlaxoSmithKline Plc.
• Mylan NV
• Allergen Inc
• Bayer AG
• Bristol-Myers Squibb
• Valeant Pharmaceuticals International Inc
• Boehringer Ingelheim
• Sorrento Therapeutics
• WEX Pharmaceuticals
• Zynerba Pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

Pain Management Drugs Market Segmentation:

By Drug Class
• NSAIDs
• Anesthetics
• Anticonvulsants
• Antimigraine Agents
• Antidepressants
• Opioids
     o Tramadol
     o Hydrocodone
     o Oxycodone
     o Others
• Nonnarcotic Analgesics
By Indication
• Arthritic Pain
• Neuropathic Pain
• Cancer Pain
• Chronic Back Pain
• Postoperative Pain
• Migraine
• Fibromyalgia
• Muscle sprain/strain
• Bone fracture 
• Acute appendicitis
• Others
By Pain Type 
• Chronic pain 
• Acute pain
By Region
• North America
• Europe
• Asia-Pacific
• Rest of the world

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Pain Management Drugs Market by drug class, by indication, by pain type and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
           1.1. Objectives of the Study 
           1.2. Market Definition 
           1.3. Market Scope 
                   1.3.1. Years Considered for the Study
                   1.3.2. Market Covered
           1.4. Currency 
           1.5. Limitations 
           1.6. Stakeholders 
 2.  Research Methodology 
           2.1. Research Data 
                   2.1.1. Secondary Data
                           2.1.1.1. Key Data from Secondary Sources
                   2.1.2. Primary Data
                            2.1.2.1. Key Data from Primary Sources
           2.2. Market Size Estimation 
           2.3. Market Breakdown and Data Triangulation 
           2.4. Assumptions for the Study  
3. Executive Summary
           3.1. Market Outlook
           3.2. Segment Outlook
           3.3. Competitive Insights
4. Global Pain Management Drugs Market Variables, Trends & Scope
           4.1. Market Lineage Outlook
           4.2. Penetration and Growth Prospect Mapping
           4.3. Industry Value Chain Analysis
           4.4. Cost Analysis Breakdown
           4.5. Technology Overview
           4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances
5. Global Pain Management Drugs Market Overview
           5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                             5.1.1.1. Increasing focus of Pain Management Drugs Companies on Brand Protection
                             5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                             5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                             5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Pain Management Drugs Market Analysis Tools
           6.1. Industry Analysis - Porter’s
                   6.1.1. Supplier Power
                   6.1.2. Buyer Power
                   6.1.3. Substitution Threat
                   6.1.4. Threat from New Entrants
                   6.1.5. Competitive Rivalry
           6.2. Pestel Analysis
                   6.2.1. Political Landscape
                   6.2.2. Environmental Landscape
                   6.2.3. Social Landscape
                   6.2.4. Technology Landscape
                   6.2.5. Legal Landscape
           6.3. Major Deals And Strategic Alliances Analysis
                   6.3.1. Joint Ventures
                   6.3.2. Mergers and Acquisitions
                   6.3.3. Licensing and Partnership
                   6.3.4. Technology Collaborations
                   6.3.5. Strategic Divestments
           6.4. Market Entry Strategies
           6.5. Case Studies
7. Global Pain Management Drugs Market, By Drug Class Historical Analysis and Forecast 2020-2027 (USD Million)
           7.1. NSAIDs
           7.2. Anesthetics
           7.3. Anticonvulsants
           7.4. Antimigraine Agents
           7.5. Antidepressants
           7.6. Opioids
                   7.6.1. Tramadol
                   7.6.2. Hydrocodone
                   7.6.3. Oxycodone
                   7.6.4. Others
           7.7. Nonnarcotic Analgesics 
8. Global Pain Management Drugs Market, By Indication Historical Analysis and Forecast 2020-2027 (USD Million)
           8.1. Arthritic Pain
           8.2. Neuropathic Pain
           8.3. Cancer Pain
           8.4. Chronic Back Pain
           8.5. Postoperative Pain
           8.6. Migraine
           8.7. Fibromyalgia
           8.8. Muscle sprain/strain
           8.9. Bone fracture 
           8.10. Acute appendicitis
           8.11. Others
9. Global Pain Management Drugs Market, By Pain Type Historical Analysis and Forecast 2020-2027 (USD Million)
           9.1. Chronic pain
           9.2. Acute pain 
10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           10.1. Introduction
           10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     10.2.1. U.S.A
                     10.2.2. Canada
                     10.2.3. Mexico
           10.3. Market Size (USD Million) Forecast for North America 2020-2027 
11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           11.1. Introduction
           11.2. Regional Market Trends
           11.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     11.3.1. Brazil
                     11.3.2. Venezuela
                     11.3.3. Argentina
                     11.3.4. Rest of Latin America
           11.4. Market Size (USD Million) Forecast for Latin America 2020-2027  
12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           12.1. Introduction
           12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     12.2.1. Germany
                     12.2.2. U.K
                     12.2.3. France
                     12.2.4. Italy
                     12.2.5. Spain
                     12.2.6. Russia
                     12.2.7. Poland
                     12.2.8. Switzerland
                     12.2.9. Rest of Western Europe
           12.3. Market Size (USD Million) Forecast for Europe 2020-2027
13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           13.1. Introduction
           13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     13.2.1. Japan
                     13.2.2. China
                     13.2.3. Singapore
                     13.2.4. India
                     13.2.5. Australia and New Zealand
                     13.2.6. ASEAN
                     13.2.7. South Korea
                     13.2.8. Taiwan
                     13.2.9. Rest of Asia Pacific
           13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
           14.1. Introduction
           14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
                     14.2.1. Saudi Arabia
                     14.2.2. UAE
                     14.2.3. South Africa
                     14.2.4. Egypt
           14.3. Market Size (USD Million) Forecast for MEA 2020-2027
15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4.  North America - Market Share Analysis and Key Regional Players
    15.5.  Europe - Market Share Analysis and Key Regional Players
    15.6.  Asia Pacific - Market Share Analysis and Key Regional Players
    15.7.  Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
           16.1. Novartis AG
                     16.1.1. Company Overview
                     16.1.2. Product Portfolio
                     16.1.3. SWOT Analysis
                     16.1.4. Financial Overview
                     16.1.5. Strategic Overview
           16.2. Eli Lilly & Company
                     16.2.1. Company Overview
                     16.2.2. Product Portfolio
                     16.2.3. SWOT Analysis
                     16.2.4. Financial Overview
                     16.2.5. Strategic Overview
           16.3. Abbott Laboratories
                     16.3.1. Company Overview
                     16.3.2. Product Portfolio
                     16.3.3. SWOT Analysis
                     16.3.4. Financial Overview
                     16.3.5. Strategic Overview
           16.4. Endo Health Solutions, Inc.
                     16.4.1. Company Overview
                     16.4.2. Product Portfolio
                     16.4.3. SWOT Analysis
                     16.4.4. Financial Overview
                     16.4.5. Strategic Overview
           16.5 Purdue Pharma L.P.
                     16.5.1. Company Overview
                     16.5.2. Product Portfolio
                     16.5.3. SWOT Analysis
                     16.5.4. Financial Overview
                     16.5.5. Strategic Overview
           16.6 Pfizer, Inc.
                     16.6.1. Company Overview
                     16.6.2. Product Portfolio
                     16.6.3. SWOT Analysis
                     16.6.4. Financial Overview
                     16.6.5. Strategic Overview
           16.7. F. Hoffmann La Roche Ltd.
                     16.7.1. Company Overview
                     16.7.2. Product Portfolio
                     16.7.3. SWOT Analysis
                     16.7.4. Financial Overview
                     16.7.5. Strategic Overview
           16.8. Merck & Co. Inc.
                     16.8.1. Company Overview
                     16.8.2. Product Portfolio
                     16.8.3. SWOT Analysis
                     16.8.4. Financial Overview
                     16.8.5. Strategic Overview
           16.9. Johnson & Johnson
                     16.9.1. Company Overview
                     16.9.2. Product Portfolio
                     16.9.3. SWOT Analysis
                     16.9.4. Financial Overview
                     16.9.5. Strategic Overview
           16.10. GlaxoSmithKline Plc.
                     16.10.1. Company Overview
                     16.10.2. Product Portfolio
                     16.10.3. SWOT Analysis
                     16.10.4. Financial Overview
                     16.10.5. Strategic Overview
           16.11. Mylan NV
                     16.11.1. Company Overview
                     16.11.2. Product Portfolio
                     16.11.3. SWOT Analysis
                     16.11.4. Financial Overview
                     16.11.5. Strategic Overview
           16.12. Allergen Inc
                     16.12.1. Company Overview
                     16.12.2. Product Portfolio
                     16.12.3. SWOT Analysis
                     16.12.4. Financial Overview
                     16.12.5. Strategic Overview
           16.13. Bayer AG
                     16.13.1. Company Overview
                     16.13.2. Product Portfolio
                     16.13.3. SWOT Analysis
                     16.13.4. Financial Overview
                     16.13.5. Strategic Overview
           16.14. Bristol-Myers Squibb
                     16.14.1. Company Overview
                     16.14.2. Product Portfolio
                     16.14.3. SWOT Analysis
                     16.14.4. Financial Overview
                     16.14.5. Strategic Overview
           16.15. Valeant Pharmaceuticals International Inc
                     16.15.1. Company Overview
                     16.15.2. Product Portfolio
                     16.15.3. SWOT Analysis
                     16.15.4. Financial Overview
                     16.15.5. Strategic Overview
           16.16. Boehringer Ingelheim
                     16.16.1. Company Overview
                     16.16.2. Product Portfolio
                     16.16.3. SWOT Analysis
                     16.16.4. Financial Overview
                     16.16.5. Strategic Overview
           16.17. Sorrento Therapeutics
                     16.17.1. Company Overview
                     16.17.2. Product Portfolio
                     16.17.3. SWOT Analysis
                     16.17.4. Financial Overview
                     16.17.5. Strategic Overview
           16.18. WEX Pharmaceuticals
                     16.18.1. Company Overview
                     16.18.2. Product Portfolio
                     16.18.3. SWOT Analysis
                     16.18.4. Financial Overview
                     16.18.5. Strategic Overview
           16.19. Zynerba Pharmaceuticals.
                     16.19.1. Company Overview
                     16.19.2. Product Portfolio
                     16.19.3. SWOT Analysis
                     16.19.4. Financial Overview
                     16.19.5. Strategic Overview
17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the healthcare regulations initiated by administrations
    17.5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client

Tables

Figures